Premium
Current clinical trial design issues in hormone‐refractory prostate carcinoma
Author(s) -
Vogelzang Nicholas J.,
Crawford E. David,
Zietman Anthony
Publication year - 1998
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19980601)82:11<2093::aid-cncr3>3.0.co;2-x
Subject(s) - medicine , estramustine , vinblastine , prostate , clinical trial , oncology , refractory (planetary science) , prostate carcinoma , hormone therapy , urology , chemotherapy , prostate disease , cancer , physics , astrobiology , breast cancer
A consensus panel reviewed the literature regarding therapy for hormone‐refractory prostate carcimona and recommended further Phase III trials building on previous Phase III trials with mitroxantrone/hydrocortisone, estramustine/vinblastine, and strontium 89 . Endpoints of such future trials could be survival, tumor response, or palliative response rate.